Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
UBS
Medtronic
Citi
Federal Trade Commission
Queensland Health

Generated: April 19, 2019

DrugPatentWatch Database Preview

LOXITANE C Drug Profile

« Back to Dashboard

Which patents cover Loxitane C, and what generic alternatives are available?

Loxitane C is a drug marketed by Teva Branded Pharm and is included in one NDA.

The generic ingredient in LOXITANE C is loxapine hydrochloride. There are eight drug master file entries for this compound. Additional details are available on the loxapine hydrochloride profile page.

Summary for LOXITANE C
Drug patent expirations by year for LOXITANE C
Synonyms for LOXITANE C
13-chloro-10-(4-methylpiperazin-1-yl)-2-oxa-9-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,9,12,14-heptaene
13-chloro-10-(4-methylpiperazin-1-yl)-2-oxa-9-azatricyclo[9.4.0.0;{3,8}]pentadeca-1(11),3(8),4,6,9,12,14-heptaene
1977-10-2
1977-10-2 (Parent)
2-Chloro-11-(4-methyl-1-piperazinyl)-dibenz(b,f)(1,4)oxazepine
2-Chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine
2-Chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine monohydrochloride
2-Chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine
2-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine
2-Chloro-11-(4-methylpiperazino)dibenz[b,f][1,4]oxazepine
2-Chloro-11-(4-methylpiperazino)dibenzo(b,f)(1,4)oxazepine
27833-64-3 (succinate)
376MYL4MAL
3785AH
54810-23-0
54810-23-0 (mono-hydrochloride)
8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine
8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine hydrochloride
8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,5]benzoxazepine
8-chloro-6-(4-methylpiperazino)benzo[b][1,4]benzoxazepine;succinic acid
977L102
AB00053735_15
AB00053735_16
AC1L1H3Z
AC1L2G3B
AC1Q3ZWR
Adasuve
Adasuve (TN)
AKOS030526111
API0006785
AZ-004
BDBM22871
BPBio1_000226
BRD-K39915878-036-04-6
BRD-K39915878-036-05-3
BRD-K39915878-036-15-2
BRN 0626753
BSPBio_000204
BSPBio_003479
C07104
C18H18ClN3O
CCG-204805
CHEBI:50841
CHEMBL1201060
CHEMBL831
CL 62,362
CL 62362
CL-62362
CL-71,563
CL-71563
CL71,563
Cloxazepine
CS-1105
D02340
D08148
DB00408
Desconex (TN)
Dibenz(b,f)(1,4)oxazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-
Dibenz(b,f)(1,4)oxazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-, monohydrochloride
Dibenz[b,f][1,4]oxazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-
Dibenzacepin
Dibenzoazepine
DivK1c_006919
DTXSID70203304
DTXSID7023229
EINECS 217-835-3
GTPL205
HF 3170
HF3170
HSDB 3111
HY-17390
Hydrofluoride 3170
KBio1_001863
KBio2_000835
KBio2_003403
KBio2_005971
KBio3_002983
KBioSS_000835
L001085
LER583670J
Lopac0_000720
Lossapina
Lossapina [DCIT]
Loxapac
Loxapin
Loxapina
Loxapina [INN-Spanish]
loxapine
Loxapine (DMSO)
Loxapine (USAN/INN)
Loxapine (water)
Loxapine [USAN:BAN:INN]
Loxapine [USAN:INN:BAN]
Loxapine HCl
Loxapine hydrochloride
Loxapine monohydrochloride
Loxapinsuccinate
Loxapinum
Loxapinum [INN-Latin]
Loxepine
Loxitane
Loxitane IM
Loxitane Intramuscular
Loxitane-C Oral Suspension
LS-186470
LS-61562
LW 3170
NCGC00021145-01
NCGC00021145-02
NCGC00021145-03
NCGC00021145-04
NCGC00021145-05
NCGC00021145-06
NCGC00021145-07
NCGC00021145-08
NCGC00022279-03
NCGC00022279-04
NCGC00022279-05
Oxilapine
PDSP1_001058
PDSP2_001042
Prestwick0_000132
Prestwick1_000132
Prestwick2_000132
Prestwick3_000132
QTL1_000050
S 805
S-805
SCHEMBL41625
SCHEMBL94146
SPBio_001814
SPBio_002143
SpecPlus_000823
Spectrum_000355
Spectrum2_001737
Spectrum3_001830
Spectrum5_001857
Staccato loxapine
SUM 3170
SUM-3170
UNII-376MYL4MAL
UNII-LER583670J
W-5098
XJGVXQDUIWGIRW-UHFFFAOYSA-N
ZINC19796158

US Patents and Regulatory Information for LOXITANE C

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Branded Pharm LOXITANE C loxapine hydrochloride CONCENTRATE;ORAL 017658-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Expired US Patents for LOXITANE C

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva Branded Pharm LOXITANE C loxapine hydrochloride CONCENTRATE;ORAL 017658-001 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Teva Branded Pharm LOXITANE C loxapine hydrochloride CONCENTRATE;ORAL 017658-001 Approved Prior to Jan 1, 1982 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Fuji
Express Scripts
US Army
Johnson and Johnson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.